1) Been watching this CBD game since 2019, and honestly, it’s been a rollercoaster. The FDA’s slow approach to clear regulations really kills a lot of the momentum investors crave. Look, the potential’s huge, no doubt, but until the rules tighten up and we see consistent earnings reports, I’m still not convinced these stocks are anywhere close to a safe bet.